Wedbush Reiterates Outperform on Beam Therapeutics, Maintains $65 Price Target

Benzinga Newsdesk www.benzinga.com Positive 39.7%

Neg 0% Neu 0% Pos 39.7%

Wedbush analyst David Nierengarten reiterates Beam Therapeutics (NASDAQ:BEAM) with a Outperform and maintains $65 price target.